Can docetaxel combined prednisone effectively treat hormone refractory prostate cancer?: A protocol of systematic review and meta-analysis.
Antineoplastic Agents
/ administration & dosage
Antineoplastic Agents, Hormonal
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Docetaxel
/ administration & dosage
Humans
Male
Prednisone
/ administration & dosage
Prostatic Neoplasms
/ drug therapy
Meta-Analysis as Topic
Systematic Review as Topic
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
29 May 2020
29 May 2020
Historique:
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
7
7
2020
Statut:
ppublish
Résumé
Previous studies have reported that docetaxel combined prednisone (DP) has been used for the treatment of patients with hormone refractory prostate cancer (HRPC). However, its results are still inconsistent. Therefore, this study will synthesize the latest evidence of the efficacy and safety of DP for the treatment of patients with HRPC. Cochrane Library, PUBMED, EMBASE, Web of Science, CINAHL, CBM, and CNKI will be searched to identify randomized controlled trials published from their inception to the March 1, 2020, irrespective language and publication time restrictions. We will calculate the pooled effects of dichotomous outcomes as risk ratio and 95% confidence intervals, and that of continuous outcomes as standardized mean difference or mean difference and 95% confidence intervals. Study quality will be assessed using Cochrane risk of bias, and quality of evidence for main outcome will be evaluated using Grading of Recommendations Assessment Development and Evaluation. Statistical analysis will be performed using RevMan 5.3 software. This study will appraise the efficacy and safety of DP for the treatment of patients with HRPC. The primary outcome includes overall survival, and the secondary outcomes comprise of progression-free survival, prostate-specific antigen response rate, duration of prostate-specific antigen response, objective tumor response rate, disease-free survival, quality of life, and adverse events. The results of this study may provide helpful evidence of DP for the treatment of patients with HRPC.Systematic review registration: INPLASY202040112.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have reported that docetaxel combined prednisone (DP) has been used for the treatment of patients with hormone refractory prostate cancer (HRPC). However, its results are still inconsistent. Therefore, this study will synthesize the latest evidence of the efficacy and safety of DP for the treatment of patients with HRPC.
METHODS
METHODS
Cochrane Library, PUBMED, EMBASE, Web of Science, CINAHL, CBM, and CNKI will be searched to identify randomized controlled trials published from their inception to the March 1, 2020, irrespective language and publication time restrictions. We will calculate the pooled effects of dichotomous outcomes as risk ratio and 95% confidence intervals, and that of continuous outcomes as standardized mean difference or mean difference and 95% confidence intervals. Study quality will be assessed using Cochrane risk of bias, and quality of evidence for main outcome will be evaluated using Grading of Recommendations Assessment Development and Evaluation. Statistical analysis will be performed using RevMan 5.3 software.
RESULTS
RESULTS
This study will appraise the efficacy and safety of DP for the treatment of patients with HRPC. The primary outcome includes overall survival, and the secondary outcomes comprise of progression-free survival, prostate-specific antigen response rate, duration of prostate-specific antigen response, objective tumor response rate, disease-free survival, quality of life, and adverse events.
CONCLUSION
CONCLUSIONS
The results of this study may provide helpful evidence of DP for the treatment of patients with HRPC.Systematic review registration: INPLASY202040112.
Identifiants
pubmed: 32481418
doi: 10.1097/MD.0000000000020367
pii: 00005792-202005290-00063
doi:
Substances chimiques
Antineoplastic Agents
0
Antineoplastic Agents, Hormonal
0
Docetaxel
15H5577CQD
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20367Références
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
Jahn JL, Giovannucci EL, Stampfer MJ. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer 2015;137:2795–802.
Connolly RM, Carducci MA, Antonarakis ES. Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl 2012;14:177–86.
Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 2002;90:174–84.
Sternberg C, Fizazi K. The relevance of continued medical castration for patients with castration resistant prostate cancer. Ann Urol 2011;2:34–9.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
Pagliarulo V. Androgen deprivation therapy for prostate cancer. Adv Exp Med Biol 2018;1096:1–30.
Joseph JS, Lam V, Patel MI. Preventing osteoporosis in men taking androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 2019;2:551–61.
Edmunds K, Tuffaha H, Galvão DA, et al. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review. Support Care Cancer 2020;28:2079–93.
Kluger J, Roy A, Chao HH. Androgen deprivation therapy and cognitive function in prostate cancer. Curr Oncol Rep 2020;22:24.
Shore ND, Antonarakis ES, Cookson MS, et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines. Prostate 2020;80:527–44.
Aloysius H, Hu L. Targeted prodrug approaches for hormone refractory prostate cancer. Med Res Rev 2015;35:554–85.
Nemes A, Tomuleasa C, Kacso G. The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. J BUON 2014;19:357–64.
Keizman D, Maimon N, Gottfried M. Metastatic hormone refractory prostate cancer: new treatment horizon. Harefuah 2012;151:545–9.
Keizman D, Maimon N, Gottfried M. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions. Am J Clin Oncol 2014;37:289–96.
Shen YJ, Bian XJ, Xie HY, et al. Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety. Zhonghua Wai Ke Za Zhi 2012;50:539–42.
Nayyar R, Sharma N, Gupta NP. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. Int J Urol 2009;16:726–31.
Machiels JP, Mazzeo F, Clausse M, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26:5261–8.
Saad F, Ruether D, Ernst S, et al. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int 2008;102:551–5.
Galli L, Fontana A, Galli C, et al. Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. Br J Cancer 2007;97:1613–7.
Shimazui T, Kawai K, Miyanaga N, et al. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 2007;37:603–8.
Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556–63.
Boehmer A, Anastasiadis AG, Feyerabend S, et al. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Anticancer Res 2005;25:4481–6.
Protheroe A. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer? Nat Clin Pract Oncol 2005;2:68–9.
Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:3343–51.
Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147–51.
Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.